Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Fifty patients without AF but undergoing cavotricuspid isthmus ablation for recurrent paroxysmal or persistent AFL were assigned to also receive or not receive same-session PVI ablation.

English Edition. Medscape. English; Deutsch; Español; Français; Português; Univadis ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Atrial flutter catheter ablation in patients without a history of atrial fibrillation reduced risk for death, stroke, HF and AF compared with medical management, according to an abstract presented ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ablation (PFA) system.

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

The second phase of the trial included the addition of studying the focal FARAPOINT™ Pulsed Field Ablation Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter, ...

Notably, instances of spasm reached 77.8% when the ablation line was situated superiorly along the mitral isthmus -- yet did not happen in any of the eight cases where the line was situated ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with ...